Navigation Links
Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
Date:11/13/2012

WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging (MRI) technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint. The findings were presented at the annual meeting of the American College of Rheumatology (ACR) in Washington, D.C.

Positive results of the placebo-controlled 12-week portion of the study were presented at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology in June 2012.[1] Patients taking baricitinib 4 mg or 8 mg once daily reported significant differences in ACR20, ACR50 and ACR70 responses compared with patients taking placebo. Data from the 12- to 24-week portion of the study, which did not include a placebo control, showed that patients who continued to receive 2 mg, 4 mg or 8 mg baricitinib once daily doses maintained or improved ACR20, ACR50 and ACR70 responses. The following chart defines the percentage of patients that achieved ACR20, ACR50 and ACR70 at 24 weeks of treatment with baricitinib.Response at 24 weeks2 mg(n=52) 4 mg
(n=52)8 mg
(n=50)ACR2063

78

73ACR5020

48

55ACR7010

28

24"These data are important because collectively they show patients experienced improvement with baricitinib as early as week two that was sustained through week 24," said Mark Genovese, M.D., the James Raitt professor of medi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  The Broad Institute today announced an unprecedented ... Stanley aimed at galvanizing scientific research on ... molecular understanding to hundreds of millions of people ... commitment – the largest ever in psychiatric research ... general – will support research by a collaborative ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Quorum Review IRB, ... service for large clinical trials called Quick Step™ . ... designed to address the research industry’s need for seamless study ... service is available for studies planning 50 or more North ... combined planned North American site count of 80 or more. ...
(Date:7/22/2014)... , July 22, 2014  United Therapeutics Corporation ... it will release its second quarter 2014 financial ... 2014. United Therapeutics will host a ... 9:00 a.m. Eastern Time.  The teleconference is accessible ... A rebroadcast of the teleconference will be available ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... test solutions with the debut of its fluorescent ... of Clinical Chemistry (AACC) meeting in Chicago, July ... or bench top versions, the HRDR-300 is a ... pending technology to analyze fluorescent lateral flow immunoassays ...
Breaking Biology Technology:$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2
... Webcast and Conference Call Scheduled for Tuesday, May 13th at ... Therapeutics, Inc.,(Nasdaq: IMRX ) today announced that the Company ... 13, 2008, at 5:00 p.m. ET to discuss,first quarter 2008 ... ImaRx,s corporate website at, http://www.imarx.com and will be archived ...
... DIEGO, May 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ... ended,March 31, 2008., Total revenues in the first ... in the first quarter of 2007, and included $2.0 ... Ltd,and $0.6 million in patent reimbursements from Arena,s collaborations ...
... augment Quintiles Consulting offerings, RESEARCH TRIANGLE ... today announced that it has signed an ... and market research,consulting firm located in Boston ... The acquisition of Eidetics will strengthen ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 8Quintiles Signs Agreement to Acquire Eidetics 2
(Date:7/22/2014)... type of immune cell widely believed to exacerbate ... and multiple sclerosis (MS), can actually protect the ... slow the progression of neurodegenerative diseases, according to ... journal Nature Communications . , The research ... the Department of Neurosciences at Cleveland Clinic,s Lerner ...
(Date:7/22/2014)... Not much is known about the the genus of ... after a new one was recently discovered in the ... city of Jaen. A description of it appears in ... http://www.insectscience.org/14.92/ ). , The new species, Conosimus ... Spanish hemipterologist, for his contributions to the taxonomy of ...
(Date:7/21/2014)... July 21, 2014 (Toronto) As part of a ... and Mental Health (CAMH) have helped identify over 100 ... of developing schizophrenia, in what is the largest genomic ... findings, published online in Nature , point to ... could lead to new approaches to treating the disorder, ...
Breaking Biology News(10 mins):Cleveland Clinic researchers discover neuroprotective role of immune cell 2International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3
... PHILADELPHIA A study published in the December issue ... the American Association for Cancer Research, suggests that selenium, ... may aid in the prevention of high-risk bladder cancer. ... levels in 767 individuals newly diagnosed with bladder cancer ...
... Rods and cones coexist peacefully in healthy retinas. Both types ... signals when they detect light, which is the first step ... a codependent relationship between the two that can be destructive. ... them to the grave, leading to blindness. A new study ...
... examines genetic variants associated with nine metabolic traits and ... a population unselected for current disease. The traits are ... 2 diabetes, blood pressure, inflammation and lipid levels. ... about their health: these data will help researchers to ...
Cached Biology News:Selenium may prevent high risk-bladder cancer 2Progression of retinal disease linked to cell starvation 2Genes for 9 health indicators 2Genes for 9 health indicators 3
... Ion Chromatography requirements, IonQuest will ... The newly developed conductivity detector ... exceptionally ultra-low drift . The ... creates even higher sensitivities for ...
... fast and easy method for the ... from mammalian tissues. Most of the ... outer membranes. The kit contains extraction ... proteome profiling. Also included is a ...
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... DNA transformation can be difficult to achieve ... presence of one or more restriction and ... that is recognized as "foreign". TypeOne™ Restriction ... transformation efficiencies in bacterial strains with type ...
Biology Products: